HMGA2 overexpression plays a critical role in the progression of esophageal squamous carcinoma

Oncotarget. 2016 May 3;7(18):25872-84. doi: 10.18632/oncotarget.8288.

Abstract

Esophageal Squamous Cell Carcinoma (ESCC) is the most common esophageal tumor worldwide. However, there is still a lack of deeper knowledge about biological alterations involved in ESCC development. High Mobility Group A (HMGA) protein family has been related with poor outcome and malignant cell transformation in several tumor types. In this way, the aim of this study was to analyze the expression of HMGA1 and HMGA2 expression in ESCC and their role in crucial cellular features. We evaluated HMGA1 and HMGA2 mRNA expression in 52 paired ESCC and normal surrounding tissue samples by qRT-PCR. Here, we show that HMGA2, but not HMGA1, is overexpressed in ESCC samples. This result was further confirmed by the immunohistochemical analysis. Indeed, accordingly to mRNA expression data, HMGA2, but not HMGA1, was overexpressed in approximately 90% of ESCC samples, while it was barely expressed in the respective control. Conversely, HMGA1, but not HMGA2, was overexpressed in esophageal adenocarcinoma samples. Interestingly, HMGA2 abrogation attenuated the malignant phenotype of two ESCC cell lines, suggesting that HMGA2 overexpression is involved in ESCC progression.

Keywords: HMGA proteins; cancer progression; diagnostic marker; esophageal cancer; malignant phenotype reversion.

MeSH terms

  • Adult
  • Aged
  • Area Under Curve
  • Biomarkers, Tumor / analysis
  • Carcinoma, Squamous Cell / pathology*
  • Disease Progression
  • Esophageal Neoplasms / pathology*
  • Esophageal Squamous Cell Carcinoma
  • Female
  • HMGA2 Protein / metabolism*
  • Humans
  • Male
  • Middle Aged
  • ROC Curve

Substances

  • Biomarkers, Tumor
  • HMGA2 Protein